Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma

Despite markedly improved treatment options for metastatic melanoma, resistance to targeted therapies such as BRAF inhibitors (BRAFi) or BRAFi plus MEK inhibitors (MEKi) remains a major problem. Our aim was to characterize progression on BRAFi therapy and outcome of subsequent treatment. One hundred...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Med
Autors principals: Hassel, Jessica C., Buder‐Bakhaya, Kristina, Bender, Carolin, Zimmer, Lisa, Weide, Benjamin, Loquai, Carmen, Ugurel, Selma, Slynko, Alla, Gutzmer, Ralf
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2017
Matèries:
Clinical Cancer Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5773979/
https://ncbi.nlm.nih.gov/pubmed/29266761
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1267
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars